PGLYRP1 and coronary artery disorder: Long-term treatment of mice with recombinant PGLYRP1 was associated with both increased atherogenic lesions and reduced fractional shortening of the left ventricle, suggesting that PGLYRP1 may be a potential biomarker for coronary artery disease and heart failure [78].